Pyxis Oncology, Inc.
PYXS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001782223
In the last 90 days, Pyxis Oncology, Inc. insiders filed 1 open-market purchase and 0 sales; 76 institutions reported holding it in 13F filings for Q2 2026, worth $101.1M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Pyxis Oncology, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 39 | 38 | −1 |
| Shares | 20.0M | 19.4M | −590.2K (−2.9%) |
| Value | $47.7M | $38.3M | −$9.38M (−19.7%) |
New holders (5)
Institutions that held Pyxis Oncology, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| OrbiMed Advisors LLC | 848,252 | $1.67M | 0.03% |
| Charles Schwab Investment Management Inc | 17,739 | $35.0K | 0.00% |
| Prelude Capital Management, LLC | 11,052 | $22.0K | 0.00% |
| Two Sigma Advisers, LP | 10,400 | $20.0K | 0.00% |
| Royal Bank of Canada | 192 | $0 | 0.00% |
Sold out (6)
Institutions that held Pyxis Oncology, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| RTW Investments, LP | 682,220 | $1.62M |
| Ergoteles LLC | 36,415 | $87.0K |
| Susquehanna International Group, LLP | 14,466 | $34.0K |
| Goldman Sachs Group Inc | 12,882 | $31.0K |
| Legal & General Group Plc | 833 | $2.00K |
| New York State Common Retirement Fund | 108 | $0 |